Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

26.06.23	Lilly Declares Third-Quarter 2023 Dividend (PR Newswire)
24.06.23	Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes (PR Newswire)
24.06.23	Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 we... (PR Newswire)
21.06.23	US FDA approves Jardiance® (empagliflozin) for the treatment of type 2 diabetes in children 10 years and older (PR Newswire)
21.06.23	FDA Approves Boehringer Ingelheim' Jardiance And Synjardy To Treat Pediatric Type 2 Diabetes (RTTNews)
20.06.23	Lilly to present new research in the treatment of diabetes and obesity at the American Diabetes Association's® 83rd Scientific Sessions (PR Newswire)
20.06.23	Lilly Teams up with the American Diabetes Association and Adam Duvall to Launch "Tap the Cap" (PR Newswire)
20.06.23	Eli Lilly To Acquire DICE Therapeutics For $48/share All-cash Deal (RTTNews)
20.06.23	Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology (PR Newswire)
16.06.23	First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention (PR Newswire)
02.06.23	Lilly Highlights Verzenio® (abemaciclib) and Jaypirca™ (pirtobrutinib) Data at 2023 ASCO® Annual Meeting (PR Newswire)
30.05.23	Lilly to Participate in Goldman Sachs Global Healthcare Conference (PR Newswire)
22.05.23	Lilly ESG Report Highlights Progress Towards Sustainability Goals (PR Newswire)
18.05.23	Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine (PR Newswire)
11.05.23	Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting (PR Newswire)
09.05.23	Lilly's Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation (PR Newswire)
09.05.23	Eli Lilly Reports Interim Results From The Phase 2 Study Of Mirikizumab (RTTNews)
09.05.23	Lilly Discloses First-in-Class, Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative Colitis (PR Newswire)
03.05.23	Eli Lilly: Donanemab Meets Primary Endpoint In Phase 3 Study Of Early Alzheimer's Disease (RTTNews)
01.05.23	Lilly Declares Second-Quarter 2023 Dividend (PR Newswire)
01.05.23	Lilly Says Lebrikizumab Improved 'face Or Hand Dermatitis' At 16 Weeks (RTTNews)
01.05.23	Up to 73% of Atopic Dermatitis Patients Taking Lilly's Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis (PR Newswire)
27.04.23	Lilly Q1 Profit Down, Misses View; Lifts FY23 Forecast; Stock Up In Pre Market (RTTNews)
27.04.23	Eli Lilly And Co. Q1 Profit Decreases, misses estimates (RTTNews)
27.04.23	Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum (PR Newswire)
27.04.23	Eli Lilly: Tirzepatide Achieves Up To 15.7% Weight Loss In Results From SURMOUNT-2 (RTTNews)
27.04.23	Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2 (PR Newswire)
24.04.23	Lilly To Sell BAQSIMI For At Least $500 Mln In Cash (RTTNews)
24.04.23	Lilly to Divest BAQSIMI to Amphastar (PR Newswire)
17.04.23	Eli Lilly To Invest Additional $1.6 Bln, Commits 200 New Jobs At LEAP Innovation Park (RTTNews)
17.04.23	Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities (PR Newswire)
13.04.23	U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab (PR Newswire)
13.04.23	Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement (PR Newswire)
22.03.23	Roche, Lilly To Develop Elecsys Amyloid Plasma Panel To Boost Early Diagnosis Of Alzheimer's Disease (RTTNews)
17.03.23	Sanofi To Cut U.S. List Price Of Its Most-prescribed Insulin By 78% (RTTNews)
14.03.23	Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
09.03.23	Lilly's Solanezumab Fails In Alzheimer's Prevention Trial (RTTNews)
08.03.23	Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease (PR Newswire)
08.03.23	Lilly : FDA Accepts SNDA For Jardiance For Children 10 Years & Older With Type 2 Diabetes (RTTNews)
08.03.23	US FDA accepts supplemental New Drug Application for Jardiance® for children 10 years and older with type 2 diabetes (PR Newswire)
06.03.23	Intensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according t... (PR Newswire)
03.03.23	U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer (PR Newswire)
01.03.23	Eli Lilly Announces Aggressive Price Cuts For Insulins; Announces Expansion Of Insulin Value Program (RTTNews)
01.03.23	Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month (PR Newswire)
21.02.23	Lilly to Participate in Cowen's 43rd Annual Health Care Conference (PR Newswire)
13.02.23	Lilly and IABL Collaborate to Ensure Patient Access to High-Quality Affordable Insulin in Bangladesh (PR Newswire)
07.02.23	Lilly to Participate in SVB Securities Global Biopharma Conference (PR Newswire)
03.02.23	Lilly to Participate in Guggenheim Oncology Conference (PR Newswire)
02.02.23	Lilly Lifts FY23 Earnings View Above Market On Updated Tax Rate - Update (RTTNews)
02.02.23	Eli Lilly And Co. Reveals Rise In Q4 Bottom Line (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

16:02		Dow Jones 30 Industrial-Wert Merck-Aktie: So viel Verlust hätte ein Investment in Merck von vor einem Jahr bedeutet
16:02		S&P 500-Papier Pfizer-Aktie: So viel Verlust hätte ein Investment in Pfizer von vor einem Jahr bedeutet
16:02		S&P 500-Wert Eli Lilly-Aktie: So viel hätte eine Investition in Eli Lilly von vor 5 Jahren abgeworfen
14.04.25		Pfizer-Aktie dennoch fester: Entwicklung von Abnehmpille gestoppt
14.04.25		DAX 40-Wert Merck-Aktie: So viel Verlust hätte eine Merck-Investition von vor 3 Jahren eingebracht
14.04.25		SMI-Papier Novartis-Aktie: Wäre eine Novartis-Investition von vor einem Jahr rentabel gewesen?
14.04.25		Neue Analyse: Jefferies & Company Inc. bewertet Bayer-Aktie mit Hold
14.04.25		Erste Schätzungen: Pfizer stellt Ergebnisse des abgelaufenen Quartals vor

16:02

Dow Jones 30 Industrial-Wert Merck-Aktie: So viel Verlust hätte ein Investment in Merck von vor einem Jahr bedeutet

16:02

S&P 500-Papier Pfizer-Aktie: So viel Verlust hätte ein Investment in Pfizer von vor einem Jahr bedeutet

16:02

S&P 500-Wert Eli Lilly-Aktie: So viel hätte eine Investition in Eli Lilly von vor 5 Jahren abgeworfen

14.04.25

Pfizer-Aktie dennoch fester: Entwicklung von Abnehmpille gestoppt

14.04.25

DAX 40-Wert Merck-Aktie: So viel Verlust hätte eine Merck-Investition von vor 3 Jahren eingebracht

14.04.25

SMI-Papier Novartis-Aktie: Wäre eine Novartis-Investition von vor einem Jahr rentabel gewesen?

14.04.25

Neue Analyse: Jefferies & Company Inc. bewertet Bayer-Aktie mit Hold

14.04.25

Erste Schätzungen: Pfizer stellt Ergebnisse des abgelaufenen Quartals vor

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Holcim	89.10	3.05 %	K V
Part Grp Hldg	1’084.50	2.75 %	K V
Zurich Insur Gr	553.60	2.52 %	K V
Swiss Life Hldg	775.80	2.43 %	K V
Geberit	559.60	2.15 %	K V
Sonova Hldg	234.00	-0.68 %	K V
CieFinRichemont	135.80	-0.88 %	K V
UBS Group	23.20	-1.11 %	K V
Swiss Re	139.80	-1.48 %	K V
Logitech Intl	59.66	-1.71 %	K V

Eli Lilly Aktie VALOR 947556 / ISIN US5324571083

Nachrichten zu Eli Lilly

Aktien Top/Flop

Eli Lilly Peer Group Nachrichten

Meistgelesene Nachrichten